Novasep, Lysogene partner for gene therapy

By The Science Advisory Board staff writers

May 26, 2020 -- Novasep and Lysogene announced that the parties have inked an agreement for the development and manufacturing of an adeno-associated viral vector (AAV)-based gene therapy drug candidate (LYS-GM101) for the treatment of GM1 gangliosidosis, a neuronopathic lysosomal storage disorder.

Under the agreement, the companies will also consolidate their partnership on the development and manufacturing of Lysogene's lead gene therapy product, LYS-SAF302, which is currently in late-phase clinical trials. Novasep will bring their expertise in manufacturing and production to help Lysogene in clinical development and to shorten the transition to commercial manufacturing.

If you like this content, please share it with a colleague!

Related Reading

Avrobio moves forward with gene therapy candidate
Avrobio released preclinical data for AVR-RD-03, lentiviral gene therapy for Pompe disease, at the American Society of Gene and Cell Therapy annual meeting...

Thermo Fisher to double viral vector manufacturing capacity
Thermo Fisher Scientific is expanding its viral vector development and manufacturing services with construction of a new commercial manufacturing site...

Fujifilm Diosynth partners with Oxgene for gene therapy
Fujifilm Diosynth Biotechnologies has partnered with Oxgene to deliver gene therapy products with a 25% reduction in production time, the company reported...